**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 73325

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism**

Carrasco-Ruiz FM *et al*. GLS superior than LVEF for myocardial dysfunction in ESRD

Maria Fernanda Carrasco-Ruiz, Antonio Ruiz-Rivera, Marvin A Soriano-Ursúa, Carlos Martinez-Hernandez, Leticia Manuel-Apolinar, Carmen Castillo-Hernandez, Gustavo Guevara-Balcazar, Eunice D Farfán-García, Ana Mejia-Ruiz, Ivan Rubio-Gayosso, Teresa Perez-Capistran

**Maria Fernanda Carrasco-Ruiz, Marvin A Soriano-Ursúa, Teresa Perez-Capistran,** Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico

**Antonio Ruiz-Rivera, Carlos Martinez-Hernandez,** Department of Cardiology, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico

**Leticia Manuel-Apolinar,** Endocrine Research Unit, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico

**Carmen Castillo-Hernandez, Gustavo Guevara-Balcazar,** Department of Cardiovascular Pharmacology, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico

**Eunice D Farfán-García,** Department of Biochemistry, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico

**Ana Mejia-Ruiz,** Education Research, Comisión Nacional Para la Mejora Continua de la Educación, Ciudad de México 03900, Mexico

**Ivan Rubio-Gayosso,** Postgraduate Studies and Research Section,Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico

**Teresa Perez-Capistran,** Department of Physiology, Instituto Politécnico Nacional, Mexico City 11340, Ciudad de México, Mexico

Maria Fernanda Carrasco-Ruiz, Antonio Ruiz-Rivera, Marvin A Soriano-Ursúa, Carlos Martinez-Hernandez, Leticia Manuel-Apolinar, Carmen Castillo-Hernandez, Gustavo Guevara-Balcazar, Eunice D Farfán-García, Ana Mejia-Ruiz, Ivan Rubio-Gayosso, Teresa Perez-Capistran

**Author contributions:** Carrasco-Ruiz MF, Ruiz-Rivera A, and Perez-Capistran T conceptualized the study; Ruiz-Rivera A, Martinez-Hernandez CM and Manuel-Apolinar L done data collection; Carrasco-Ruiz MF, Ruiz-Rivera A, Mejia-Ruiz A, Soriano-Ursúa MA and Martinez-Hernandez C carried out data analysis and interpretation; Carrasco-Ruiz MF, Soriano-Ursúa MA, and Perez-Capistran T drafting article; and All authors revised and approved the final version of this manuscript.

**Supported by** the Secretaría de Investigación y Posgrado of the Instituto Politécnico Nacional; the Comisión de Operación y Fomento de Actividades Académicas of the Instituto Politécnico Nacional; and the Consejo Nacional de Ciencia y Tecnología.

**Corresponding author: Teresa Perez-Capistran, PhD, Academic Research,** Department of Physiology, Instituto Politécnico Nacional, Plan de San Luis y Diaz Miron s/n Col. Casco de Sto Tomas, Mexico City 11340, Ciudad de México, Mexico. ruper-05@hotmail.com

**Received:** November 17, 2021

**Revised:** January 7, 2022

**Accepted:** **April 4, 2022**

**Published online:**

**Abstract**

BACKGROUND

The estimation of left ventricular ejection fraction (LVEF) by 2D echocardiography (2D-ECHO) is the most used tool to assess LV systolic function (LVSF).Global longitudinal strain (GLS) has recently been suggested as a superior method for several evaluations. This study explored the association and prevalence of LV systolic dysfunction (LVSD) by using these methods in patients with end-stage renal disease (ESRD) and severe hyperparathyroidism (SHPTH); both associated with cardiovascular events (CEs).

AIM

To evaluate the myocardial function in patients with ESRD and SHPTH by using the GLSand LVEF measured through conventional 2D-ECHO.

METHODS

In62 patients with ESRD and SHPTH, asymptomatic, and without a history of CEs, LVSF was evaluated by 2D-ECHO, obtaining the EF, by the Simpson biplane method, and GLS by speckle tracking.

RESULTS

The total patients with ESRD had a preserved LVEF (> 50%) but abnormal GLS (< 13.55%). Additionally, multivariate analysis showed an independent association of GLS and serum parathyroid hormone (PTH), LV mass index, and hemoglobin. Also, PTH was independently associated with lateral e' wave and tricuspid regurgitation velocity.

CONCLUSION

In patients with SHPTH linked to ESRD, the use of GLS by 2D-ECHO is a more sensitive tool than LVEF for detecting LVSD.

**Key Words:** Left ventricular hypertrophy; Systolic dysfunction; Global longitudinal strain; End-stage renal disease; Parathormone

Carrasco-Ruiz MF, Ruiz-Rivera A, Soriano-Ursúa MA, Martinez-Hernandez C, Manuel-Apolinar L, Castillo-Hernandez C, Guevara-Balcazar G, Farfán-García ED, Mejia-Ruiz A, Rubio-Gayosso I, Perez-Capistran T. Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism . *World J Cardiol* 2022; In press

**Core tip:** This study compared global longitudinal strain (GLS) with the often-used left ventricular ejection fraction to estimate ventricular dysfunction in patients with end-stage renal disease. GLS had an advantage to detect dysfunction, but also, it was found that the parathyroid hormone levels were attractive as a complementary tool to predict patient status.

**INTRODUCTION**

Cardiovascular disease (CVD) is the most common cause of morbidity and mortality in patients with end-stage renal disease (ESRD). Heart failure (HF) is a cardiovascular event (CE) that may occur simultaneously in these patients[1-3]. Chronic elevated pressure, volume overload and nonhemodynamic factors including inappropriate activation of the renin–angiotensin–aldosterone system (RAAS) and alterations in calcium–phosphorus mineral metabolism by an excess of parathyroid hormone[4,5] are involved in left ventricular hypertrophy (LVH)[6,7], then, in the myocardial dysfunction in ESRD[3,8].

LV ejection fraction (LVEF) calculated by 2D echocardiography (2D-ECHO) is the most widely used echocardiographic parameter that provides objective information on LV systolic function (LVSF), and it has been used as a prognostic and treatment indicator for CVD[9-11]. However, in some studies involving patients with ESRD, LVEF fails as a sensitive parameter for detecting subclinical data of LV systolic dysfunction (LVSD). In this sense, research groups have explored new variables and methods to increase the early and efficient diagnosis and prognosis of patients with LVSD[12]. Thus, for example, determination of left atrial volume[13], natriuretic peptides (NPs)[14] and catecholamines metabolites in serum (related to sympathetic overactivity)[15] have been proposed as advantageous tools.

Special attraction is on alternative 2D-ECHO methods, specifically, predialysis and peritoneal dialysis patients with preserved LVEF (> 50%) showed reduced GLS (15%), which was associated with an increased risk of HF hospitalization and increased mortality[3]. Thus, GLS may be a better tool to assess subclinical changes in LVSD in particular cases, for example, where the LVEF is preserved as in those patients subject to volume or pressure overload, or both[3,16]. Additionally, studies have mentioned that the variables used to define a preserved LVEF and a reduced GLS are associated with differences between the characteristics of the population studied (race, stage of ESRD, risk factors, and comorbidities). However, despite this variability, GLS is an important echocardiographic tool that might be used in patients with ESRD to identify those with a high-risk prognosis for developing HF or other CEs.

In the present study, a comparison was made from echocardiographic changes in patients with ESRD and hyperparathyroidism, the degree of LV remodeling, LVSF using 2D-ECHO, EF (by Simpson’s method), and GLS (by Speckle tracking). Additionally, plasma parathyroid hormone (PTH) concentration was considered to increase ability to detect LVSD in patients with ESRD and hyperparathyroidism (a common hormone elevated in ESRD, but poorly explored or linked to CEs in these patients).

**MATERIALS AND METHODS**

This study was done in patients with asymptomatic ESRD with renal replacement therapy (RRT; dialysis and hemodialysis) and with no history of CEs. The degree of LVDD (I, II or III) was assigned by applying the Nagueh SF, 2020 recommendations[17], and the measurement of plasma PTH in relation to the LVSF and LV diastolic function (LVDF) was explored.

This retrospective and observational study included a total of 77 individuals divided into three groups: healthy individuals with no known disease (Control; *n* = 15), age > 18 years, both genders; patients with ESRD on hemodialysis (ESRD-HD; *n* = 31) and patients with ESRD on peritoneal dialysis (ESRD-PD; *n* = 31). The ESRD groups came from the Nephrology service of Centro Médico SXXI, IMSS. This study was carried out from February 2019 to October 2020.

All patients with ESRD maintained their RRT and were supplemented with calcium and calcitriol following clinical practice guidelines[18]. Those individuals with hemodynamic alterations increasing risk on their physical integrity were excluded. A complete medical history was taken. Demographic, clinical and comorbid characteristics were collected. A blood sample was collected in the morning before the RRT, and 4 h later, echocardiography was performed.

***Echocardiography***

Transthoracic echocardiography images were obtained using a commercially available ultrasound system (Ecocardiograph iE33; Philips). Standard 2D Doppler, color, pulsed and continuous wave echocardiographic acquisitions were made. LV dimensions were obtained from images in a long axis parasternal view, and LV mass and body surface area-corrected indexed LV mass were calculated. In addition, the relative wall thickness was obtained as a ratio of (2 × RWTd) / LVIDd, where RWTd is the back-wall thickness, and LVIDd is the internal diameter of the LV at the end of diastole. The LV end-diastolic and systolic volumes were then measured from the apical views (two and four chambers) using the Simpson biplane method[19]. Mitral annulus early diastolic velocity (E') was identified by tissue Doppler imaging in a four-chamber view. Mitral inflow velocities, such as transmitral peak early passive filling velocity (E), late diastolic filling velocity caused by atrial contraction (A), and deceleration time, were determined using Pw-Doppler over the mitral valve in four-chamber views. The degree of diastolic dysfunction of each patient was assessed[17].

GLS was evaluated by obtaining LV grayscale scatter images from all three apical views. From the 2D images, the endocardial border was manually drawn during the end of the systole, and the thickness of the myocardial region of interest was adjusted to include the entire thickness of the myocardial wall. In each echocardiographic view, the myocardium was automatically divided into six segments. Therefore, the overall maximum systolic longitudinal pressure was calculated by averaging the maximum systolic values of all 18 segments, derived from the three apical views (six segments in each apical view) adjusted to the heart rate.

***Biostatistics***

Continuous variables are expressed as the mean ± SD. Continuous variables were compared between groups using ANOVA and then a **2 test. A multivariate logistic regression analysis was used, which included the clinical and echocardiographic parameters associated with the univariate analysis as independent variables. *p* < 0.05 was considered statistically significant. The statistical analysis was performed with SPSS version 20.

**RESULTS**

The characteristics were as follows from the total population: 48 participants were female (62%) and 29 (38%) male. According to the division, in the control group, the age was 34 ± 13 years, body mass index (BMI) 23.4 kg/m2, 67% female and 33% male, without relevant comorbidities. The ESRD-HD group age was 36 ± 2 years, BMI 23.3 kg/m2, 84% female and 16% male, 90% presented with hypertension and 6.45% with type 2 diabetes mellitus (T2DM). In the ESRD-PD group, age was 34 ± 10 years, BMI 22.4 kg/m2, 39% female and 61% male, all presented with hypertension, and 16% with T2DM (Table 1).

Patients with ESRD had severe refractory hyperparathyroidism (PTH > 650 pg/mL), but calcium (Ca2+), phosphorus (P), and calcium/phosphorus (Ca2+/P) ratio levels were within normal ranges. There was no significant difference from the control group, suggesting an average plasma calcitriol level. All of our population with ESRD showed LVH. LV mass and LV mass index (LVMI) were substantially increased; LVH concentric type was predominant (ESRD-HD = 80.65% and ESRD-PD = 93.35%) (Table 2).

The 2D-ECHO variables of the population studied are shown (illustrative case in Figure 1), demonstrating that by Simpson’s method, LVEF was preserved, while the GLS was substantially reduced compared to the control group (21% ± 0.58% *vs* 13.93% and 13.18%; *P* < 0.0001; control *vs* ESRD-HD and ESRD-PD). The average GLS was −13.55% in all populations with ESRD. This shows that LVEF does not establish systolic dysfunction in patients diagnosed with ESRD, even though they have systolic dysfunction by GLS evaluation (Table 3).

In the bivariate analysis, an association of GLS with hemoglobin, hypertension, PTH, LVH and LVMI was shown. In comparison, the multivariate analysis showed an independent association of GLS and hemoglobin, PTH and LVMI (Table 4).

This study analyzed the LVDF by obtaining the pattern of transmitral flow rates and their relationship with the tissue velocities at the mitral ring level. The above is related to the fact that the increase in LV filling pressures is the primary physiological consequence of LVDD. These variables were significantly altered in the ESRD population compared to the controls (Table 3).

The tricuspid regurgitation velocity (TRV) and E/e' ratio associated with the decrease in the E/A ratio and the e' septal lateral waves reflect the pattern of altered relaxation and myocardial distensibility during the diastolic phase. Previously reported recommendations were applied[17], and it was found that among individuals with ESRD-HD, 67.74% (*n* = 21) had grade I, 22.58% (*n* = 7) grade II, and 9.67% (*n* = 3) grade III LVDD. Among individuals with ESRD-PD, 84.37% (*n* = 27) had grade I and 15.63% (*n* = 4) had grade II LVDD. The univariate and multivariate analyses (Table 5) showed the associations between the variables studied and PTH. An independent association of serum PTH and lateral e' wave and TRV was shown.

**DISCUSSION**

Despite the extended use of EF to evaluate myocardial dysfunction, recent proposals promise to improve detection of cardiovascular dysfunction. As an example, 2D-ECHO for measuring left atrial volume is useful to predict diastolic dysfunction in ESRD patients[13]. Measuring plasma biomarkers has been suggested to extend diagnostic advantages. Thus, plasma NP levels are reported to be linked to cardiac remodeling[18], survival[19] and volume expansion-related LV disorders[20] in patients with ESRD[14].

Currently, 2D-ECHO methods remain core in diagnosis and evaluation of patients with CEs. The identification of LV strain changes is crucial for early cardiac damage detection in ESRD[21-24]. This study showed that increased LVMI, low hemoglobin levels but high PTH are independent factors associated with GLS alterations. The overall average GLS was 13.55%, with LVEF > 50% in the patient population, which according to the literature, is related to poor prognosis[25-29]. In this case, it was suggested that in the population with ESRD, the determination of GLS by 2D-ECHO is highly recommended for the assessment of LVSF; being a more powerful tool than LVEF, which can identify systolic myocardial damage[3,18,19] during follow-up of patients[29].

In patients with ESRD, bone mineral disorder is correlated with adverse outcomes from cardiovascular causes[25,30,31]. Recently, the mineral disorders in the early stages of ESRD have been associated with myocardial remodeling, which is a crucial point for LVH development[31-33]. In our study population, the presence of LVH was 100%, with a predominance of the concentric type. In this regard, some studies have directly implicated hyperphosphatemia and hypercalcemia in developing LVH[7,30] by regulating several factors[31,34-36]. However, it must be considered that the kidney is an essential target organ for PTH, and the interaction with its receptor activates multiple signaling pathways[37-39], triggering numerous changesin the kidney and some other systems[40]. As strong evidence of the PTH role in cardioremodeling, studies have shown that patients undergoing parathyroidectomy (PTX) have a substantial reduction in LV mass[41]; in contrast, patients with severe hyperparathyroidism and PTX showed a significant decrease in the risk of death from all causes[42]. Patients in the current study were supplemented with calcium or analogs; plasma values of Ca, P and Ca/P ratio were within normal ranges, while PTH levels were higher than reference values (PTH > 650 pg/mL). Multivariate analysis showed an independent association of GLS and PTH, suggesting a putative role of PTH in LVSF by diverse mechanisms, including those related to remodeling of subendocardial fibers[43].

Additional research is required to elucidate the mechanisms involved in the PTH modulation of the structure and function of the cardiomyocytes, as the pleiotropic effects are attributed to the interaction of PTH with its receptor [33,40].

PTH serum levels showed an independent association with some diastolic function parameters (Table 5): particularly e' lateral wave and TRV. The alterations in diastolic function primarily involve the mechanisms of myocardial relaxation and compliance. The signaling pathways involving remodeling and cardiac fibrosis in patients with ESRD are complex and multifactorial, involving alterations in the extracellular matrix proteins, type I collagen, elastin, fibroblasts, and myofibroblasts[9,44-46], which reduce myocardial compliance. These effector pathways involve PTH and 25-hydroxy vitamin D3 and several other factors[34-39,46-51]. Elevated levels of catecholamine by sympathetic overactivity are reported to be linked to LV disorders and volume excess in ESRD patients[15].

Finally, our results are in line with recent reports supporting that conventional speckle-tracking echocardiography[52-54] might help identify LVSD in patients with ESRD and preserved LVEF. Early detection of myocardial morphological and functional changes in the routine evaluation of patients with ESRD can tackle the early stages of disease-independent modifiable risk factors that are associated with adverse CEs.

**CONCLUSION**

An accurate diagnosis is increasingly important in this type of patient with ESRD with systolic and diastolic myocardial function evaluation, offering integrated, lower cost, and noninvasive information. The use of new diagnostic tools is essential to provide the population with new targeted therapies for defined subsets of patients who may be at risk of developing potential complications. The use of GLS by 2D-ECHO is a more sensitive tool than LVEF to detect of LVSD. For individuals with ESRD and severe hyperparathyroidism refractory to hormone replacement but with normal Ca/P levels, it is essential to recommend the use of GLS as a diagnostic and prognostic tool for systolic myocardial dysfunction; albeit if patients have preserved LVEF.

**ARTICLE HIGHLIGHTS**

***Research background***

Echocardiography is the most-used tool for diagnosis of myocardial dysfunction. Among 2D-ecocardiography (2D-ECHO) methods, ejection fraction (EF) is the most used. In patients with myocardial dysfunction and end-stage renal disease (ESRD) parathyroid hormone (PTH) is often altered.

***Research motivation***

Recent echocardiography methods are being compared with ejection fraction. Global longitudinal strain (GLS) is among the most explored. Additional serum biomarkers could help to increase sensibility of tests.

***Research objectives***

To compare the EF and global strain methods for detecting myocardial dysfunction. To measure the potential role of some biomarkers as complementary tools in patient evaluation.

***Research methods***

Left ventricular systolic function (LVSF) was evaluated in62 patients with ESRD with altered levels of PTH. LVSF was evaluated by performing 2D-ECHO, obtaining the EF, by the Simpson biplane method, and GLS by speckle tracking.

***Research results***

All patients with ESRD had preserved LVEF (> 50%) but abnormal GLS (< 13.55%). PTH was independently associated with lateral e' wave and tricuspid regurgitation velocity.

***Research conclusions***

In patients with elevated PTH and ESRD, the use of GLS by 2D-ECHO is a more-sensitive tool than LVEF for detecting myocardial dysfunction.

***Research perspectives***

GLS and serum PTH should be widely explored as potential sensitive tools to detect myocardial dysfunction in patients with ESRD. The mechanisms linked to this disrupted condition should be analyzed. Alternative echocardiography methods and biomarkers should be compared to select the most-sensitive and accurate tools.

**REFERENCES**

1 **Gansevoort RT**, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013; **382**: 339-352 [PMID: 23727170 DOI: 10.1016/S0140-6736(13)60595-4]

2 **Shah S**, Meganathan K, Christianson AL, Leonard AC, Thakar CV. Pre-dialysis acute care hospitalizations and clinical outcomes in dialysis patients. *PLoS One* 2019; **14**: e0209578 [PMID: 30650094 DOI: 10.1371/journal.pone.0209578]

3 **Hensen LCR**, Goossens K, Delgado V, Abou R, Rotmans JI, Jukema JW, Bax JJ. Prevalence of left ventricular systolic dysfunction in pre-dialysis and dialysis patients with preserved left ventricular ejection fraction. *Eur J Heart Fail* 2018; **20**: 560-568 [PMID: 29164753 DOI: 10.1002/ejhf.1077]

4 **Tonelli M**, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. *J Am Soc Nephrol* 2006; **17**: 2034-2047 [PMID: 16738019 DOI: 10.1681/ASN.2005101085]

5 **Tamulėnaitė E**, Žvirblytė R, Ereminienė R, Žiginskienė E, Ereminienė E. Changes of Left and Right Ventricle Mechanics and Function in Patients with End-Stage Renal Disease Undergoing Haemodialysis. *Medicina (Kaunas)* 2018; **54** [PMID: 30428607 DOI: 10.3390/medicina54050087]

6 **Kim IY**, Kim JH, Kim MJ, Lee DW, Hwang CG, Han M, Rhee H, Song SH, Seong EY, Lee SB. Plasma neutrophil gelatinase-associated lipocalin is independently associated with left ventricular hypertrophy and diastolic dysfunction in patients with chronic kidney disease. *PLoS One* 2018; **13**: e0205848 [PMID: 30325973 DOI: 10.1371/journal.pone.0205848]

7 **Di Lullo L**, Gorini A, Russo D, Santoboni A, Ronco C. Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. *Cardiorenal Med* 2015; **5**: 254-266 [PMID: 26648942 DOI: 10.1159/000435838]

8 **Herzog CA**. Kidney disease in cardiology. *Nephrol Dial Transplant* 2009; **24**: 34-37 [PMID: 19028753 DOI: 10.1093/ndt/gfn637]

9 **Ponikowski P**, Jankowska EA. Pathogenesis and clinical presentation of acute heart failure. *Rev Esp Cardiol (Engl Ed)* 2015; **68**: 331-337 [PMID: 25743769 DOI: 10.1016/j.rec.2015.02.001]

10 **McGuire DK**, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N; CARMELINA Investigators. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. *Circulation* 2019; **139**: 351-361 [PMID: 30586723 DOI: 10.1161/CIRCULATIONAHA.118.038352]

11 **Kümler T**, Gislason GH, Køber L, Torp-Pedersen C. Persistence of the prognostic importance of left ventricular systolic function and heart failure after myocardial infarction: 17-year follow-up of the TRACE register. *Eur J Heart Fail* 2010; **12**: 805-811 [PMID: 20494923 DOI: 10.1093/eurjhf/hfq071]

12 **Halliday BP**, Senior R, Pennell DJ. Assessing left ventricular systolic function: from ejection fraction to strain analysis. *Eur Heart J* 2021; **42**: 789-797 [PMID: 32974648 DOI: 10.1093/eurheartj/ehaa587]

13 **Tripepi G**, Mattace-Raso F, Mallamaci F, Benedetto FA, Witteman J, Malatino L, Zoccali C. Biomarkers of left atrial volume: a longitudinal study in patients with end stage renal disease. *Hypertension* 2009; **54**: 818-824 [PMID: 19635983 DOI: 10.1161/HYPERTENSIONAHA.109.136804]

14 **Mallamaci F**, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Stancanelli B, Malatino LS; CREED Investigstors. The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. *Kidney Int* 2001; **59**: 1559-1566 [PMID: 11260421 DOI: 10.1046/j.1523-1755.2001.0590041559.x]

15 **Abd ElHafeez S**, Tripepi G, Stancanelli B, Dounousi E, Malatino L, Mallamaci F, Zoccali C. Norepinephrine, left ventricular disorders and volume excess in ESRD. *J Nephrol* 2015; **28**: 729-737 [PMID: 25708914 DOI: 10.1007/s40620-015-0182-4]

16 **Kamperidis V**, Marsan NA, Delgado V, Bax JJ. Left ventricular systolic function assessment in secondary mitral regurgitation: left ventricular ejection fraction *vs* speckle tracking global longitudinal strain. *Eur Heart J* 2016; **37**: 811-816 [PMID: 26685140 DOI: 10.1093/eurheartj/ehv680]

17 **Nagueh SF**. Diastology: 2020-A practical guide. *Echocardiography* 2020; **37**: 1919-1925 [PMID: 32476157 DOI: 10.1111/echo.14742]

18 **Cataliotti A**, Malatino LS, Jougasaki M, Zoccali C, Castellino P, Giacone G, Bellanuova I, Tripepi R, Seminara G, Parlongo S, Stancanelli B, Bonanno G, Fatuzzo P, Rapisarda F, Belluardo P, Signorelli SS, Heublein DM, Lainchbury JG, Leskinen HK, Bailey KR, Redfield MM, Burnett JC Jr. Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. *Mayo Clin Proc* 2001; **76**: 1111-1119 [PMID: 11702899 DOI: 10.4065/76.11.1111]

19 **Zoccali C**, Mallamaci F, Benedetto FA, Tripepi G, Parlongo S, Cataliotti A, Cutrupi S, Giacone G, Bellanuova I, Cottini E, Malatino LS. Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. *J Am Soc Nephrol* 2001; **12**: 1508-1515 [PMID: 11423580 DOI: 10.1681/ASN.V1271508]

20 **Enia G**, Mallamaci F, Benedetto FA, Panuccio V, Parlongo S, Cutrupi S, Giacone G, Cottini E, Tripepi G, Malatino LS, Zoccali C. Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. *Nephrol Dial Transplant* 2001; **16**: 1459-1464 [PMID: 11427641 DOI: 10.1093/ndt/16.7.1459]

21 **Khwaja A**. KDIGO clinical practice guidelines for acute kidney injury. *Nephron Clin Pract* 2012; **120**: c179-c184 [PMID: 22890468 DOI: 10.1159/000339789]

22 **Ewe SH**, Haeck ML, Ng AC, Witkowski TG, Auger D, Leong DP, Abate E, Ajmone Marsan N, Holman ER, Schalij MJ, Bax JJ, Delgado V. Detection of subtle left ventricular systolic dysfunction in patients with significant aortic regurgitation and preserved left ventricular ejection fraction: speckle tracking echocardiographic analysis. *Eur Heart J Cardiovasc Imaging* 2015; **16**: 992-999 [PMID: 25733208 DOI: 10.1093/ehjci/jev019]

23 **de Brito Galvao JF**, Nagode LA, Schenck PA, Chew DJ. Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. *J Vet Emerg Crit Care (San Antonio)* 2013; **23**: 134-162 [PMID: 23566108 DOI: 10.1111/vec.12036]

24 **Drüeke TB**. Hyperparathyroidism in Chronic Kidney Disease. 2021 Oct 18. In: Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000– [PMID: 25905209]

25 **Ke QQ**, Xu HB, Bai J, Xiong L, Li MM. Evaluation of global and regional left ventricular myocardial work by echocardiography in patients with chronic kidney disease. *Echocardiography* 2020; **37**: 1784-1791 [PMID: 33084159 DOI: 10.1111/echo.14864]

26 **Panoulas VF**, Sulemane S, Konstantinou K, Bratsas A, Elliott SJ, Dawson D, Frankel AH, Nihoyannopoulos P. Early detection of subclinical left ventricular myocardial dysfunction in patients with chronic kidney disease. *Eur Heart J Cardiovasc Imaging* 2015; **16**: 539-548 [PMID: 25428945 DOI: 10.1093/ehjci/jeu229]

27 **Tadic M**, Cuspidi C. Left ventricular strain and arterial hypertension: Is longitudinal strain ready for primetime? *J Clin Hypertens (Greenwich)* 2020; **22**: 683-685 [PMID: 32073217 DOI: 10.1111/jch.13833]

28 **Park JH**, Park JJ, Park JB, Cho GY. Prognostic Value of Biventricular Strain in Risk Stratifying in Patients With Acute Heart Failure. *J Am Heart Assoc* 2018; **7**: e009331 [PMID: 30371332 DOI: 10.1161/JAHA.118.009331]

29 **Park JJ**, Mebazaa A, Hwang IC, Park JB, Park JH, Cho GY. Phenotyping Heart Failure According to the Longitudinal Ejection Fraction Change: Myocardial Strain, Predictors, and Outcomes. *J Am Heart Assoc* 2020; **9**: e015009 [PMID: 32519555 DOI: 10.1161/JAHA.119.015009]

30 **de Albuquerque Suassuna PG**, Sanders-Pinheiro H, de Paula RB. Uremic Cardiomyopathy: A New Piece in the Chronic Kidney Disease-Mineral and Bone Disorder Puzzle. *Front Med (Lausanne)* 2018; **5**: 206 [PMID: 30087898 DOI: 10.3389/fmed.2018.00206]

31 **Kaesler N**, Babler A, Floege J, Kramann R. Cardiac Remodeling in Chronic Kidney Disease. *Toxins (Basel)* 2020; **12** [PMID: 32150864 DOI: 10.3390/toxins12030161]

32 **Fujii H**, Joki N. Mineral metabolism and cardiovascular disease in CKD. *Clin Exp Nephrol* 2017; **21**: 53-63 [PMID: 28062938 DOI: 10.1007/s10157-016-1363-8]

33 **Iseri K**, Dai L, Chen Z, Qureshi AR, Brismar TB, Stenvinkel P, Lindholm B. Bone mineral density and mortality in end-stage renal disease patients. *Clin Kidney J* 2020; **13**: 307-321 [PMID: 32699616 DOI: 10.1093/ckj/sfaa089]

34 **Faul C**, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M. FGF23 induces left ventricular hypertrophy. *J Clin Invest* 2011; **121**: 4393-4408 [PMID: 21985788 DOI: 10.1172/JCI46122]

35 **Tanaka S**, Fujita S, Kizawa S, Morita H, Ishizaka N. Association between FGF23, α-Klotho, and Cardiac Abnormalities among Patients with Various Chronic Kidney Disease Stages. *PLoS One* 2016; **11**: e0156860 [PMID: 27400031 DOI: 10.1371/journal.pone.0156860]

36 **Custódio MR**, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V. Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. *Nephrol Dial Transplant* 2012; **27**: 1437-1445 [PMID: 21825304 DOI: 10.1093/ndt/gfr447]

37 **Verdelli C**, Corbetta S. MECHANISMS IN ENDOCRINOLOGY: Kidney involvement in patients with primary hyperparathyroidism: an update on clinical and molecular aspects. *Eur J Endocrinol* 2017; **176**: R39-R52 [PMID: 27601015 DOI: 10.1530/EJE-16-0430]

38 **Vilardaga JP**, Romero G, Friedman PA, Gardella TJ. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. *Cell Mol Life Sci* 2011; **68**: 1-13 [PMID: 20703892 DOI: 10.1007/s00018-010-0465-9]

39 **Vilardaga JP**, Gardella TJ, Wehbi VL, Feinstein TN. Non-canonical signaling of the PTH receptor. *Trends Pharmacol Sci* 2012; **33**: 423-431 [PMID: 22709554 DOI: 10.1016/j.tips.2012.05.004]

40 **Fujii H**. Association between Parathyroid Hormone and Cardiovascular Disease. *Ther Apher Dial* 2018; **22**: 236-241 [PMID: 29707916 DOI: 10.1111/1744-9987.12679]

41 **McMahon DJ**, Carrelli A, Palmeri N, Zhang C, DiTullio M, Silverberg SJ, Walker MD. Effect of Parathyroidectomy Upon Left Ventricular Mass in Primary Hyperparathyroidism: A Meta-Analysis. *J Clin Endocrinol Metab* 2015; **100**: 4399-4407 [PMID: 26445115 DOI: 10.1210/jc.2015-3202]

42 **Li W**, Zhang M, Du S, Yu Y, Liu J, Zhang L, Yao L. Impact of parathyroidectomy on survival among haemodialysis patients: A prospective cohort study. *Nephrology (Carlton)* 2016; **21**: 133-138 [PMID: 26199009 DOI: 10.1111/nep.12564]

43 **Sanchis L**, Andrea R, Falces C, Poyatos S, Vidal B, Sitges M. Differential Clinical Implications of Current Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. *J Am Soc Echocardiogr* 2018; **31**: 1203-1208 [PMID: 30241926 DOI: 10.1016/j.echo.2018.08.011]

44 **Lan HY**. Diverse roles of TGF-β/Smads in renal fibrosis and inflammation. *Int J Biol Sci* 2011; **7**: 1056-1067 [PMID: 21927575 DOI: 10.7150/ijbs.7.1056]

45 **Chen L**, Yang T, Lu DW, Zhao H, Feng YL, Chen H, Chen DQ, Vaziri ND, Zhao YY. Central role of dysregulation of TGF-β/Smad in CKD progression and potential targets of its treatment. *Biomed Pharmacother* 2018; **101**: 670-681 [PMID: 29518614 DOI: 10.1016/j.biopha.2018.02.090]

46 **van Ballegooijen AJ**, Visser M, Kestenbaum B, Siscovick DS, de Boer IH, Gottdiener JS, deFilippi CR, Brouwer IA. Relation of vitamin D and parathyroid hormone to cardiac biomarkers and to left ventricular mass (from the Cardiovascular Health Study). *Am J Cardiol* 2013; **111**: 418-424 [PMID: 23168286 DOI: 10.1016/j.amjcard.2012.10.021]

47 **Almahmoud MF**, Soliman EZ, Bertoni AG, Kestenbaum B, Katz R, Lima JAC, Ouyang P, Miller PE, Michos ED, Herrington DM. Fibroblast Growth Factor-23 and Heart Failure With Reduced Versus Preserved Ejection Fraction: MESA. *J Am Heart Assoc* 2018; **7**: e008334 [PMID: 30371180 DOI: 10.1161/JAHA.117.008334]

48 **Dobaczewski M**, Chen W, Frangogiannis NG. Transforming growth factor (TGF)-β signaling in cardiac remodeling. *J Mol Cell Cardiol* 2011; **51**: 600-606 [PMID: 21059352 DOI: 10.1016/j.yjmcc.2010.10.033]

49 **Biernacka A**, Dobaczewski M, Frangogiannis NG. TGF-β signaling in fibrosis. *Growth Factors* 2011; **29**: 196-202 [PMID: 21740331 DOI: 10.3109/08977194.2011.595714]

50 **Falcón D**, Galeano-Otero I, Calderón-Sánchez E, Del Toro R, Martín-Bórnez M, Rosado JA, Hmadcha A, Smani T. TRP Channels: Current Perspectives in the Adverse Cardiac Remodeling. *Front Physiol* 2019; **10**: 159 [PMID: 30881310 DOI: 10.3389/fphys.2019.00159]

51 **Raggi P**, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? *J Am Coll Cardiol* 2002; **39**: 695-701 [PMID: 11849871 DOI: 10.1016/s0735-1097(01)01781-8]

52 **Geyer H**, Caracciolo G, Abe H, Wilansky S, Carerj S, Gentile F, Nesser HJ, Khandheria B, Narula J, Sengupta PP. Assessment of myocardial mechanics using speckle tracking echocardiography: fundamentals and clinical applications. *J Am Soc Echocardiogr* 2010; **23**: 351-69; quiz 453-5 [PMID: 20362924 DOI: 10.1016/j.echo.2010.02.015]

53 **Kizilca O**, Ozmen D, Demircan T, Yilmaz N, Kir M, Soylu A, Unal N, Kavukcu S. Evaluation of left ventricular systolic functions in two-dimensional speckle-tracking echocardiography in children with chronic renal failure. *Cardiol Young* 2021; **31**: 421-428 [PMID: 33308338 DOI: 10.1017/S1047951120004205]

54 **Wang X**, Hong J, Zhang T, Xu D. Changes in left ventricular and atrial mechanics and function after dialysis in patients with end-stage renal disease. *Quant Imaging Med Surg* 2021; **11**: 1899-1908 [PMID: 33936973 DOI: 10.21037/qims-20-961]

**Footnotes**

**Institutional review board statement:** The study was approved by Comité de Ética del Centro Médico Nacional, Siglo XXI, IMSS, México.

**Informed consent statement:** All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

**Conflict-of-interest statement:** The authors here declare no conflicts of interests or relationships regarding the industry at the date of this submission.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** November 17, 2021

**First decision:** December 27, 2021

**Article in press:**

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** Mexico

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B


Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Cabezuelo AS, Spain; Malatino L, Italy; Papazafiropoulou A, Greece **S-Editor:** Ma YJ **L-Editor:** Kerr C **P-Editor:** Ma YJ

**Figure Legends**



**Figure 1 Illustrative 2D echocardiography.** Top: control patient; Bottom: patient with end-stage renal disease (ESRD) and severe hyperparathyroidism (SHPTH). The ejection fraction (EF) by the Simpson method was calculated as a function of the endocardial borders at end-diastole and end-systole in the apical projection of two cavities. A and C (left): in the control patient, left ventricular EF (LVEF) was 56% (A), and 61% in the patient with ESRD and SHPTH (C). 2D ECHO ST real-time showed longitudinal deformation (B and D, right). The deformation pattern in the control patient (B) was normal, with global longitudinal strain (GLS) = 19%, and GLS was abnormal (14%) in the patient with ESRD and SHPTH (D).

**Table 1 Demographic and clinical variables in the study groups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Demographicvariables** | **Control, *n* = 15** | **ESRD-HD, *n* = 15** | **ESRD-PD, *n* = 15** | **Total, *n* = 15** |
| Age(yr) | 34 ± 13 | 36 ± 2 | 34 ± 10 | 34.6 ± |
| Gender, *n* (%) | F = 10 (67), M = 5 (33) | F = 26 (84), M = 5 (16) | F = 12 (39), M = 19 (61) | F = 48 (62), M = 29 (38) |
| BMI(kg/m2 ) | 23.4 | 23.3 | 22.4 | 23 ± |
| Hypertension, *n* (%) | N/A | 28 (90) | 31 (100) | 59 (77) |
| DMT2, *n* (%) | N/A | 2 (6.45) | 5 (16) | 7 (9.09) |

ESRD: end-stage renal disease; ESRD-HD: ESRD on hemodialysis; ESRD-PD: ESRD on peritoneal dialysis; F: Female; M: Male; BMI: body mass index; n/a: Not available.

**Table 2 Biochemical and left ventricular remodeling variables in the study groups: control, end-stage renal disease on hemodialysis and end-stage renal disease on peritoneal dialysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Control** | **ESRD-HD** | **ESRD-PD** | ***p* value** |
| Biochemical |  |  |  |  |
| PTH (pg/mL) | 50 ± 4.55a,c | 1188 ± 203.9 | 1188 ± 203.9 | < 0.0001 |
| Ca2+ (mg/dL) | 8.55 ± 2.34 | 8.47 ± 0.14 | 8.38 ± 0.09 | NS |
| P (mg/dL) | 4.56 ± 2.28 | 4.75 ± 0.24 | 4.75 ± 0.28 | NS |
| Ca2+/P (mg2/dL2) | 45.32 ± 1.05 | 42.31 ± 2.35 | 39.87 ± 2.5 | NS |
| Albumin (mg/dL) | 4.47 ± 0.10a,c | 4.13 ± 0.12 | 3.94 ± 0.06 | < 0.0284 |
| Hemoglobin (g/dL) | 15.3 ± 0.12a,c | 8.73 ± 0.24 | 8.91 ± 0.22 | < 0.0001 |
| LV remodeling |  |  |  |  |
| LV mass (g) | 133.8 ± 3a,c | 182.7 ± 12.2 | 186.6 ± 15 | < 0.0001 |
| LVMI (g/m2) | 70.65 ± 2.11a,c | 130.2 ± 6.24 | 127.5 ± 6.55 | < 0.0001 |
| RWT | 0.39 ± 0.016a,c | 0.51 ± 0.01 | 0.51 ± 0.02 | < 0.0001 |

The data represent the mean ± SD. ANOVA followed by a Tukey test was performed and was considered significant. a*p* < 0.05, control *vs* ESRD-HD. c*p* < 0.05, control *vs* ESRD-PD.ESRD: end-stage renal disease; ESRD-HD: ESRD on hemodialysis; ESRD-PD: ESRD on peritoneal dialysis; PTH: plasma parathyroid hormone; LV: left ventricular; LVMI: LV mass index; NS: Not significant.

**Table 3 Echocardiographic population variables control, end-stage renal disease on hemodialysis and end-stage renal disease on peritoneal dialysis**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Control** | **ESRD-HD** | **ESRD-PD** | ***P* value** |
| LVEF | 60.75 ± 1.30 | 63.5 ± 10.36 | 61.8 ± 11.19 | NS |
| GLS (%) | 21 ± 0.58a,c | 13 ± 0.72 | 12 ± 1.83 | < 0.0001 |
| LAV (mL/m2) | 33.07 ± 0.22a,c | 26.49 ± 1.4 | 25.73 ± 1.57 | < 0.0001 |
| E/A ratio | 1.25 ± 0.03a,c | 1.05 ± 0.06 | 0.91 ± 0.05 | < 0.0001 |
| E/é ratio | 5.38 ± 0.18a,c | 11.62 ± 0.96 | 12.22 ± 1.13 | < 0.0001 |
| E (cm/s) | 60.39 ± 1.71a,c | 80.19 ± 6.26 | 81.29 ± 6.97 | < 0.0001 |
| Lateral e’ (cm/s) | 13.44 ± 0.36a,c | 8.33 ± 0.43 | 7.49 ± 0.16 | < 0.0001 |
| Septal é (cm/s) | 10.85 ± 0.35a,c | 6.18 ± 0.24 | 6.49 ± 0.23 | < 0.0001 |
| TRV (m/s) | 2.21 ± 0.02a,c | 2.94 ± 0.08 | 2.80 ± 0.07 | < 0.0001 |
| LVMI (g /m2) | 70.65 ± 2.11a,c | 130.2 ± 6.24 | 127.5 ± 6.55 | < 0.0001 |
| RWT | 0.39 ± 0.016a,c | 0.51 ± 0.01 | 0.51 ± 0.02 | < 0.0001 |

The data represents mean ± SD. ANOVA followed by Tukey test was performed and was considered significant. a*p* < 0.05, control *vs* ESRD-HD. c*p* < 0.05, control *vs* ESRD-PD.ESRD: end-stage renal disease; ESRD-HD: ESRD on hemodialysis; ESRD-PD: ESRD on peritoneal dialysis; LVEF: left ventricular ejection fraction; GLS: Global longitudinal strain; LAV: left atrial volume; TRV: tricuspid regurgitation velocity; LVMI: LV mass index; NS: Not significant; RWT: Relative wall thickness.

**Table 4 Global longitudinal strain and variables association**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Univariate** | | | | | **Multivariate using significant variables** | | | | | **Multivariate by step method** | | | | |
| **B** | **β** | **95%CI for B** | | ***P* value** | **B** | **β** | **95%CI for B** | | ***P* value** | **B** | **β** | **95%CI for B** | | ***P* value** |
| **Lower limit** | **Upper limit** | **Lower limit** | **Upper limit** | **Lower limit** | **Upperlimit** |
| Association with GLS (%) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Hemoglobin | -1.09 | -0.61 | -1.42 | -0.77 | 0.00 | -0.58 | -0.32 | -1.12 | -0.05 | 0.03 | -0.62 | -0.35 | -0.99 | -0.26 | 0.00 |
| Hypertension | 5.60 | 0.54 | 3.58 | 7.61 | 0.00 | 1.52 | 0.15 | -1.44 | 4.49 | 0.31 |  |  |  |  |  |
| PTH | 0.00 | 0.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.27 | 0.00 | 0.00 | 0.01 | 0.00 | 0.29 | 0.00 | 0.00 | 0.00 |
| LVEF | -0.04 | -0.08 | -0.15 | 0.07 | 0.50 |  |  |  |  |  |  |  |  |  |  |
| LVH | 6.40 | 0.57 | 4.27 | 8.53 | 0.00 | -1.82 | -0,16 | -7.75 | 4.12 | 0.54 |  |  |  |  |  |
| LVMi | 0.06 | 0.51 | 0.04 | 0.08 | 0.00 | 0.03 | 0.28 | 0.01 | 0.05 | 0.01 | 0.03 | 0.29 | 0.01 | 0.05 | 0.00 |
| RWT | 11.36 | 0.25 | 1.27 | 21.46 | 0.03 | -1.21 | -0.03 | -10.14 | 7.73 | 0.79 |  |  |  |  |  |

95% CI: 95% confidence interval; GLS: Global longitudinal strain; PTH: plasma parathormone; LVEF: left ventricular ejection fraction; LVH: left ventricular hypertrophy; LVMI: left ventricular mass index; RWT: Relative wall thickness.

**Table 5** **Association between parathyroidism levels and left ventricular diastolic dysfunction variables**

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Variables** | **Univariate** | | | | | **Multivariate using significant variables** | | | | | **Multivariate by step method** | | | | |
| **B** | **β** | **95%CI for B** | | ***P* value** | **B** | **β** | **95%CI for B** | | ***P* value** | **B** | **β** | **95%CI for B** | | ***P* value** |
| **Lower limit** | **Upper limit** | **Lower limit** | **Upper limit** | **Lower limit** | **Upper limit** |
| Association with PTH |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| E/é ratio | 54.22 | 0.33 | 18.34 | 90.09 | 0.00 | 28.19 | 0.17 | -11.55 | 67.93 | 0.16 |  |  |  |  |  |
| é lateral | -124.,51 | -0.36 | -199.34 | -49.69 | 0.00 | -81.10 | -0.23 | -177.06 | 14.87 | 0.10 | -89.72 | -0.26 | -169.01 | -10.44 | 0.03 |
| é septal | -121.78 | -0.28 | -215.64 | -27.91 | 0.01 | -0.63 | 0.00 | -121.22 | 119.97 | 0.99 |  |  |  |  |  |
| TRV | 698.98 | 0.35 | 276.86 | 1121.10 | 0.00 | 360.73 | 0.18 | -141.53 | 862.99 | 0.16 | 500.88 | 0.25 | 53.87 | 947.89 | 0.03 |

95%CI: 95% confidence interval; PTH: plasma parathormone; TRV: tricuspid regurgitation velocity.